ubamatamab
Regeneron
['ovarian']
ph 1 trial of bispecific antibody muc16 x cd3 in heavily pretreated ovarian cancer (md prev lines 4.5): main toxicity include crs (74.4% - g1/2), 24.4% g3 anemia and 7.7 % g3 neutropenia, 1 case of icans; great 1st results 14.3% orr, 57% dcr and durable responses #esmo22 
Medical oncologist - Drug development Department (DITEP) / Interception program for cancer prevention - Gustave Roussy Cancer Center 

Cooking aficionado =)